Medchemexpress LLC Ard-2051 | 2632305-17-8 | 98.6% | 789.32 | C43H45ClN8O5 | 10 MG

Supplier:  Medchemexpress LLC HY14986210MG

ARD-2051 is a selective, orally active androgen receptor proteolysis-targeting chimera (PROTAC) degrader developed for preclinical research into AR-dependent cancers. It induces potent AR protein degradation in cell-based assays and has demonstrated favorable pharmacokinetics and oral efficacy in animal models.

• Potent AR protein degradation (DC50 ~0.6 nM).
• Orally active with demonstrated in vivo efficacy in preclinical models.
• Effective in AR-positive prostate cancer cell lines, including LNCaP and VCaP.
• Characterized pharmacokinetic profile and oral bioavailability in rodent and canine studies.
• High chemical purity suitable for research applications.
• Supplied as a solid with defined storage recommendations for stability.

Catalog No. 50-002-87344